Winklevoss Capital 将为 Leap 提供资金及战略支持，协助其设计并执行数字资产国库策略。Leap 将借助 Winklevoss Capital 的专业经验，通过参与数字资产领域，为股东创造长期价值。部分融资资金也将用于继续推进公司的治疗项目，包括 FL-501 和 Sirexatamab。后者近期已完成针对结直肠癌患者的随机对照 II 期临床试验，并将于 2025 年 10 月 19 日在德国柏林举办的欧洲肿瘤内科学会（ESMO）大会上以 Mini Oral Session 形式进行报告。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.